Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.480
-0.220 (-4.68%)
At close: Nov 18, 2026, 4:00 PM EST
4.510
+0.030 (0.67%)
After-hours: Nov 18, 2026, 7:30 PM EST
Kyverna Therapeutics Employees
Kyverna Therapeutics had 172 employees as of September 30, 2026. The number of employees increased by 43 or 33.33% compared to the same quarter last year. That makes Kyverna Therapeutics the 27,886th largest employer in the world and 3,506th in the United States.
Employees
172
Change (1Y)
43
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$917,395
Market Cap
283.23M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 172 | 43 | 33.33% |
| Jun 30, 2026 | 149 | 20 | 15.50% |
| Mar 31, 2026 | 129 | 10 | 8.40% |
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Sep 30, 2025 | 129 | 10 | 8.40% |
| Jun 30, 2025 | 129 | 17 | 15.18% |
| Mar 31, 2025 | 119 | 19 | 19.00% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Sep 30, 2024 | 119 | 30 | 33.71% |
| Jun 30, 2024 | 112 | 23 | 25.84% |
| Mar 31, 2024 | 100 | - | - |
| Dec 31, 2023 | 96 | - | - |
| Sep 30, 2023 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Nautilus Biotechnology | 128 |
| Inovio Pharmaceuticals | 112 |
| Scribe Therapeutics | 82 |
| AgomAb Therapeutics NV | 62 |
| Altimmune | 57 |
| Vicore Pharma Holding AB | 50 |
| Benitec Biopharma | 24 |
KYTX News
- 5 days ago - Kyverna Therapeutics participates in a conference call with JPMorgan - TheFly
- 6 days ago - Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 6 days ago - Kyverna Therapeutics reports Q EPS (68c), consensus (69c) - TheFly
- 6 days ago - Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 6 days ago - Kyverna Therapeutics Quarterly report: Q3 2026 - Filings
- 6 days ago - Kyverna Therapeutics Earnings release: Q3 2026 - Filings
- 7 days ago - Kyverna Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTX - Business Wire
- 9 days ago - Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology - GlobeNewsWire